Gain Therapeutics
GANX
GANX
24 hedge funds and large institutions have $5.68M invested in Gain Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
2% more capital invested
Capital invested by funds: $5.54M → $5.68M (+$134K)
0.61% more ownership
Funds ownership: 9.68% → 10.28% (+0.61%)
Holders
24
Holding in Top 10
–
Calls
$331K
Puts
$128K
Top Buyers
| 1 | +$245K | |
| 2 | +$199K | |
| 3 | +$84.2K | |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$60K |
| 5 |
Millennium Management
New York
|
+$56.3K |
Top Sellers
| 1 | -$85.1K | |
| 2 | -$62.3K | |
| 3 | -$60.3K | |
| 4 |
CC
Cannell Capital
Alta,
Wyoming
|
-$59.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11.2K |